Microglial Activation and Dopaminergic Cell Injury: An In Vitro Model Relevant to Parkinson's Disease

Microglial activation and oxidative stress are significant components of the pathology of Parkinson's disease (PD), but their exact contributions to disease pathogenesis are unclear. We have developed an in vitro model of nigral injury, in which lipopolysaccharide-induced microglial activation leads to injury of a dopaminergic cell line (MES 23.5 cells) and dopaminergic neurons in primary mesencephalic cell cultures. The microglia are also activated by PD IgGs in the presence of low-dose dopa-quinone- or H2O2-modified dopaminergic cell membranes but not cholinergic cell membranes. The activation requires the microglial FcγR receptor as demonstrated by the lack of activation with PD IgG Fab fragments or microglia from FcγR−/− mice. Although microglial activation results in the release of several cytokines and reactive oxygen species, only nitric oxide and H2O2appear to mediate the microglia-induced dopaminergic cell injury. These studies suggest a significant role for microglia in dopaminergic cell injury and provide a mechanism whereby immune/inflammatory reactions in PD could target oxidative injury relatively specifically to dopaminergic cells.

[1]  J. Merrill,et al.  Cytokines in inflammatory brain lesions: helpful and harmful , 1996, Trends in Neurosciences.

[2]  P. Damier,et al.  Glial cells and inflammation in parkinson's disease: A role in neurodegeneration? , 1998, Annals of neurology.

[3]  F. Rossi,et al.  beta-amyloid activates the O-2 forming NADPH oxidase in microglia, monocytes, and neutrophils. A possible inflammatory mechanism of neuronal damage in Alzheimer's disease. , 1999, The Journal of biological chemistry.

[4]  M. Beal,et al.  Excitotoxicity and nitric oxide in parkinson's disease pathogenesis , 1998, Annals of neurology.

[5]  K. Jellinger,et al.  The pathology of Parkinson's disease. , 2001, Advances in neurology.

[6]  J. Fazakerley,et al.  Specific infection and destruction of dopaminergic neurons in the substantia nigra by Theiler's virus , 1997, Journal of virology.

[7]  O. Hansson,et al.  Improving the survival of grafted dopaminergic neurons: a review over current approaches. , 2000, Cell transplantation.

[8]  W. Hall,et al.  A rat model of Parkinson's disease induced by Japanese encephalitis virus. , 1997, Journal of neurovirology.

[9]  T. Molitor,et al.  Activated microglia mediate neuronal cell injury via a nitric oxide mechanism. , 1992, Journal of immunology.

[10]  S. Shimohama,et al.  Dopamine D2‐type agonists protect mesencephalic neurons from glutamate neurotoxicity: Mechanisms of neuroprotective treatment against oxidative stress , 1998, Annals of neurology.

[11]  T. Montine,et al.  Covalent Crosslinking of Neurofilament Proteins by Oxidized Catechols as a Potential Mechanism of Lewy Body Formation , 1995, Journal of neuropathology and experimental neurology.

[12]  T. Nagatsu,et al.  Interleukin (IL)-1 beta, IL-2, IL-4, IL-6 and transforming growth factor-alpha levels are elevated in ventricular cerebrospinal fluid in juvenile parkinsonism and Parkinson's disease. , 1996, Neuroscience letters.

[13]  E. Hirsch,et al.  FcεRII/CD23 Is Expressed in Parkinson’s Disease and Induces, In Vitro, Production of Nitric Oxide and Tumor Necrosis Factor-α in Glial Cells , 1999, The Journal of Neuroscience.

[14]  E. Stefani,et al.  Serum antibodies to L-type calcium channels in patients with amyotrophic lateral sclerosis. , 1992, The New England journal of medicine.

[15]  Ted M. Dawson,et al.  Inducible nitric oxide synthase stimulates dopaminergic neurodegeneration in the MPTP model of Parkinson disease , 1999, Nature Medicine.

[16]  J. Newcombe,et al.  Low density lipoprotein uptake by macrophages in multiple sclerosis plaques: implications for pathogenesis , 1994, Neuropathology and applied neurobiology.

[17]  W. Le,et al.  Antibodies from patients with Parkinson's disease react with protein modified by dopamine oxidation , 1998, Journal of neuroscience research.

[18]  T. Ørntoft,et al.  Association of IgM type anti‐GM1 antibodies and muscle strength in chronic acquired demylelinating polyneuropathy , 1998, Annals of neurology.

[19]  P. Mcgeer,et al.  Reactive microglia are positive for HLA‐DR in the substantia nigra of Parkinson's and Alzheimer's disease brains , 1988, Neurology.

[20]  S. Appel,et al.  Experimental destruction of substantia nigra initiated by Parkinson disease immunoglobulins. , 1998, Archives of neurology.

[21]  S. Appel,et al.  Experimental autoimmune nigral damage in guinea pigs , 1995, Journal of Neuroimmunology.

[22]  K. McNaught,et al.  Altered Glial Function Causes Neuronal Death and Increases Neuronal Susceptibility to 1‐Methyl‐4‐Phenylpyridinium‐ and 6‐Hydroxydopamine‐Induced Toxicity in Astrocytic/Ventral Mesencephalic Co‐Cultures , 1999, Journal of neurochemistry.

[23]  M. McMillian,et al.  Role of Protein Kinase C in Microglia‐induced Neurotoxicity in Mesencephalic Cultures , 1997, Journal of neuropathology and experimental neurology.

[24]  P. Jenner,et al.  Understanding cell death in parkinson's disease , 1998, Annals of neurology.

[25]  J. Ravetch,et al.  FcR γ chain deletion results in pleiotrophic effector cell defects , 1994, Cell.

[26]  E. Stefani,et al.  A novel N18TG2 x mesencephalon cell hybrid expresses properties that suggest a dopaminergic cell line of substantia nigra origin , 1992, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[27]  M. Mattson,et al.  Oxidized lipoproteins increase reactive oxygen species formation in microglia and astrocyte cell lines , 1999, Brain Research.

[28]  L. Colom,et al.  Cell death induced by β-amyloid 1–40 in MES 23.5 hybrid clone: the role of nitric oxide and NMDA-gated channel activation leading to apoptosis , 1995, Brain Research.

[29]  T. Nagatsu,et al.  Interleukin (IL)-1β, IL-2, IL-4, IL-6 and transforming growth factor-α levels are elevated in ventricular cerebrospinal fluid in juvenile parkinsonism and Parkinson's disease , 1996, Neuroscience Letters.

[30]  C. Marsden,et al.  Increased levels of lipid hydroperoxides in the parkinsonian substantia nigra: An HPLC and ESR study , 1994 .

[31]  G. Kreutzberg.  Microglia: a sensor for pathological events in the CNS , 1996, Trends in Neurosciences.

[32]  C. Marsden,et al.  Increased levels of lipid hydroperoxides in the parkinsonian substantia nigra: An HPLC and ESR study , 1994, Movement disorders : official journal of the Movement Disorder Society.

[33]  Haruhiko Akiyama,et al.  Rate of cell death in parkinsonism indicates active neuropathological process , 1988, Annals of neurology.

[34]  T. Saito,et al.  FcR gamma-chain is essential for both surface expression and function of human Fc gamma RI (CD64) in vivo. , 1996, Blood.

[35]  H. Wekerle,et al.  Neuronal Control of the Immune Response in the Central Nervous System: Linking Brain Immunity to Neurodegeneration , 1998, Journal of neuropathology and experimental neurology.

[36]  T. Montine,et al.  Parkinson's disease is associated with oxidative damage to cytoplasmic DNA and RNA in substantia nigra neurons. , 1999, The American journal of pathology.

[37]  J. Langston,et al.  Evidence of active nerve cell degeneration in the substantia nigra of humans years after 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine exposure , 1999, Annals of neurology.

[38]  A. Mayer.  Therapeutic implications of microglia activation by lipopolysaccharide and reactive oxygen species generation in septic shock and central nervous system pathologies: a review. , 1998, Medicina.

[39]  J. Jankovic,et al.  Effects of cerebrospinal fluid from patients with Parkinson disease on dopaminergic cells. , 1999, Archives of neurology.

[40]  B. Wainer,et al.  In vitro cell cultures as a model of the basal forebrain. , 1991, Advances in experimental medicine and biology.

[41]  J. Tajti,et al.  Nigral damage and dopaminergic hypofunction in mesencephalon‐immunized guinea pigs , 1992, Annals of neurology.

[42]  V. Perry,et al.  Heterogeneity in the distribution and morphology of microglia in the normal adult mouse brain , 1990, Neuroscience.

[43]  C. Marsden,et al.  Mitochondrial Complex I Deficiency in Parkinson's Disease , 1990, Lancet.

[44]  N. Hattori,et al.  Immunohistochemical detection of 4-hydroxynonenal protein adducts in Parkinson disease. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[45]  J. Cano,et al.  Lipopolysaccharide Intranigral Injection Induces Inflammatory Reaction and Damage in Nigrostriatal Dopaminergic System , 1998, Journal of neurochemistry.

[46]  Minoru Harada,et al.  Tumor necrosis factor-α (TNF-α) increases both in the brain and in the cerebrospinal fluid from parkinsonian patients , 1994, Neuroscience Letters.

[47]  K. Jellinger,et al.  Pathology of Parkinson's disease. Changes other than the nigrostriatal pathway. , 1991, Molecular and chemical neuropathology.

[48]  A. H. V. Schapira,et al.  MITOCHONDRIAL COMPLEX I DEFICIENCY IN PARKINSON'S DISEASE , 1989, The Lancet.